公开(公告)号：WO2016049236A1

公开(公告)日：2016-03-31

申请号：PCT/US2015/051793

申请日：2015-09-23

Applicant: NUSIRT SCIENCES, INC.

Inventor： ZEMEL, Michael ,  BRUCKBAUER, Antje

IPC: A61K9/48

CPC classification number: A61K31/28 ,  A61K31/05 ,  A61K31/155 ,  A61K31/198 ,  A61K31/36 ,  A61K31/455 ,  A61K31/706 ,  A61K45/06 ,  A61K2300/00

Abstract: Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia are provided herein. Such compositions can contain synergizing amounts of leucine and/or one or more leucine metabolites in combination with nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites, and with at least one or more anti-diabetic agents. Such compositions can contain sub-therapeutic amounts of nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites, and/or sub-therapeutic amounts of one or more anti-diabetic agents that can achieve the same therapeutic efficacy as therapeutic amounts of said compositions in diabetes and/or hyperlipidemia medicaments. The composition can also reduce the side effects associated with treatment using anti-diabetic agents and/or nicotinic acid.

Abstract translation: 本文提供了用于治疗糖尿病和/或高脂血症的组合物，方法和试剂盒。 这样的组合物可以包含与烟酸，烟酰胺核苷和/或烟酸代谢物以及与至少一种或多种抗糖尿病药物组合的协同量的亮氨酸和/或一种或多种亮氨酸代谢物。 这样的组合物可以包含次治疗量的烟酸，烟酰胺核苷和/或烟酸代谢物，和/或亚治疗量的一种或多种抗糖尿病药，其可以达到与治疗量相同的治疗功效， 糖尿病和/或高脂血症药物。 组合物还可以减少与使用抗糖尿病剂和/或烟酸的治疗相关的副作用。

公开(公告)号：WO2014078459A1

公开(公告)日：2014-05-22

申请号：PCT/US2013/069957

申请日：2013-11-13

Applicant: NUSIRT SCIENCES, INC.

Inventor： ZEMEL, Michael ,  BRUCKBAUER, Antje ,  BAGGETT, Brooke

IPC: A61K31/04 ,  A61K31/195 ,  A61K38/54

CPC classification number: A61K31/519 ,  A61K9/0053 ,  A61K31/05 ,  A61K31/19 ,  A61K31/198 ,  A61K31/4415 ,  A61K31/675 ,  A61K31/7048 ,  A61K45/06 ,  A61K2300/00

Abstract: Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions comprise a combination of a PDE 5 inhibitor, such as sildenafil or icariin, and resveratrol, and a branched amino acid such as leucine, or its metabolite.

Abstract translation: 本文提供了可用于诱导脂肪酸氧化或线粒体生物发生增加，减轻体重增加，诱导体重减轻或增加Sirt1，Sirt3或AMPK活性的组合物和方法。 这样的组合物包含PDE5抑制剂如西地那非或淫羊藿苷和白藜芦醇和支链氨基酸如亮氨酸或其代谢物的组合。

公开(公告)号：WO2019161211A2

公开(公告)日：2019-08-22

申请号：PCT/US2019/018230

申请日：2019-02-15

Applicant: NUSIRT SCIENCES, INC.

Inventor： ZEMEL, Michael ,  BRUCKBAUER, Antje ,  BANERJEE, Jheelam

IPC: A61K31/575

Abstract: Methods useful for reducing or preventing hepatic steatosis and NASH are provided herein. Such methods may comprise administering to a subject in need thereof an FXR agonist in combination with an amount of a branched amino acid in free amino acid form, such as leucine, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.

公开(公告)号：WO2014152016A1

公开(公告)日：2014-09-25

申请号：PCT/US2014/026816

申请日：2014-03-13

Applicant: NUSIRT SCIENCES, INC.

Inventor： ZEMEL, Michael ,  BRUCKBAUER, Antje

IPC: A61K31/51 ,  A61P3/10 ,  C12P13/06

CPC classification number: A61K31/435 ,  A23L33/15 ,  A23L33/175 ,  A23V2002/00 ,  A61K31/05 ,  A61K31/198 ,  A61K31/455 ,  A61K31/706 ,  A61K45/06 ,  A61K47/183 ,  A61K2300/00 ,  A23V2200/3262 ,  A23V2250/0628 ,  A23V2250/7046

Abstract: Compositions, methods, and kits useful for treating hyperlipidemic conditions are provided herein. Such compositions can contain synergizing amounts of nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites in combination with leucine and/or a leucine metabolite, with or without resveratrol.

Abstract translation: 本文提供了可用于治疗高脂血症的组合物，方法和试剂盒。 这样的组合物可以含有与亮氨酸和/或亮氨酸代谢物结合的协同量的烟酸，烟酰胺核苷和/或烟酸代谢物，有或没有白藜芦醇。

公开(公告)号：WO2017040407A8

公开(公告)日：2017-03-09

申请号：PCT/US2016/049272

申请日：2016-08-29

Applicant: NUSIRT SCIENCES, INC.

Inventor： ZEMEL, Michael ,  BRUCKBAUER, Antje

IPC: A61K9/12 ,  A61K31/05 ,  A61K31/192 ,  A61K31/198 ,  A61K31/235 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/505 ,  A61K45/06 ,  A61K47/18 ,  A61K9/20 ,  A61K9/22

Abstract: Methods useful for sustaining a reduction of non-alcoholic steatohepatitis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or PDE5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.

Abstract translation: 本文提供了用于维持非酒精性脂肪性肝炎减少的方法。 此类方法可包括向需要其的受试者单独或与一定量的游离氨基酸形式的支链氨基酸组合或其代谢物一起施用瑟土因途径活化剂和/或PDE5抑制剂。 本文还提供用于实施本文所述任何方法的组合物和试剂盒。

公开(公告)号：WO2015131152A1

公开(公告)日：2015-09-03

申请号：PCT/US2015/018182

申请日：2015-02-27

Applicant: NUSIRT SCIENCES INC.

Inventor： ZEMEL, Michael ,  BRUCKBAUER, Antje

IPC: A61P3/04

CPC classification number: A61K31/198 ,  A61K31/05 ,  A61K31/155 ,  A61K31/352 ,  A61K31/4439 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/522 ,  A61K31/53 ,  A61K31/7048 ,  A61K45/06 ,  A61K2300/00

Abstract: Methods useful for reducing or preventing hepatic steatosis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or PDE5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.

Abstract translation: 本文提供了可用于减少或预防肝脂肪变性的方法。 这样的方法可以包括向有需要的受试者施用sirtuin途径活化剂和/或PDE5抑制剂，或与一定量的游离氨基酸形式的支链氨基酸或其代谢物组合施用。 本文还提供了用于实施本文所述的任何方法的组合物和试剂盒。

公开(公告)号：WO2018058109A1

公开(公告)日：2018-03-29

申请号：PCT/US2017/053448

申请日：2017-09-26

Applicant: NUSIRT SCIENCES, INC.

Inventor： ZEMEL, Michael ,  BRUCKBAUER, Antje

IPC: A61K31/155 ,  A61K31/455 ,  A23L33/175

CPC classification number: C07D233/88 ,  A61P3/00

Abstract: Methods and compounds useful for reducing, treating, preventing, or sustaining the reduction of a metabolic disease or disorder are provided herein. Also provided herein are compositions and kits for practicing any of the methods described herein.

Abstract translation: 本文提供了用于减少，治疗，预防或维持代谢疾病或病症减轻的方法和化合物。 本文还提供用于实施本文所述任何方法的组合物和试剂盒。

公开(公告)号：WO2017040407A1

公开(公告)日：2017-03-09

申请号：PCT/US2016/049272

申请日：2016-08-29

Applicant: NUSIRT SCIENCES, INC.

Inventor： ZEMEL, Michael ,  BRUCKBAUER, Antje

IPC: A61K9/12 ,  A61K9/20 ,  A61K9/22 ,  A61K31/05 ,  A61K31/192 ,  A61K31/198 ,  A61K31/235 ,  A61K31/505 ,  A61K31/455 ,  A61K31/4415 ,  A61K45/06 ,  A61K47/18

CPC classification number: A61K31/519 ,  A61K9/20 ,  A61K9/48 ,  A61K31/155 ,  A61K31/19 ,  A61K31/198 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/495 ,  G01N2333/9108 ,  G01N2333/91188 ,  G01N2800/085 ,  A61K2300/00

Abstract: Methods useful for sustaining a reduction of non-alcoholic steatohepatitis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or PDE5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.

Abstract translation: 本发明提供了用于维持非酒精性脂肪性肝炎的减少的方法。 这样的方法可以包括向有需要的受试者施用sirtuin途径活化剂和/或PDE5抑制剂，或与一定量的游离氨基酸形式的支链氨基酸或其代谢物组合施用。 本文还提供了用于实施本文所述的任何方法的组合物和试剂盒。

公开(公告)号：WO2014149434A1

公开(公告)日：2014-09-25

申请号：PCT/US2014/018418

申请日：2014-02-25

Applicant: NUSIRT SCIENCES, INC.

Inventor： ZEMEL, Michael ,  BRUCKBAUER, Antje

IPC: A23K1/18

CPC classification number: A23K1/1603 ,  A23K10/18 ,  A23K10/30 ,  A23K10/37 ,  A23K20/10 ,  A23K20/142 ,  A23K20/158 ,  A23K20/163 ,  A23K20/174 ,  A23K20/30 ,  A23K40/20 ,  A23K40/25 ,  A23K40/30 ,  A23K50/42 ,  A23Y2220/00 ,  A23Y2240/00 ,  A23Y2260/00 ,  A23Y2280/00 ,  A23Y2300/00 ,  A23Y2320/00 ,  Y02P60/877

Abstract: The present invention provides for systems, compositions, methods and kits for regulating energy metabolism in pets. The systems, compositions, and kits can comprise, and methods can make use of, pet foods, pet treats, pet supplements, and pet drinks. In one aspect, the invention provides for pet food, treat, supplement, and drink compositions that comprise a combination of (a) leucine, and (b) vitamin B6, or any precursors or metabolites of (a) or (b). These combinations may be effective for reducing weight or adipose volume in the pet. In another aspect, the invention provides for methods of regulating energy metabolism by the administration of one or more compositions comprising leucine, a leucine metabolite, and/or vitamin B6. The invention also provides for kits comprising compositions of leucine, a leucine metabolite, and/or vitamin B6 packaged in an oral dose form with usage instructions.

Abstract translation: 本发明提供了用于调节宠物能量代谢的系统，组合物，方法和试剂盒。 系统，组合物和试剂盒可以包括宠物食品，宠物食品，宠物补充剂和宠物饮料的方法和方法。 一方面，本发明提供包含（a）亮氨酸和（b）维生素B6或（a）或（b）的任何前体或代谢物的组合的宠物食品，治疗，补充和饮料组合物。 这些组合对于减轻宠物的体重或脂肪体积是有效的。 另一方面，本发明提供了通过施用包含亮氨酸，亮氨酸代谢物和/或维生素B6的一种或多种组合物来调节能量代谢的方法。 本发明还提供了包含亮氨酸，亮氨酸代谢物和/或维生素B6的组合物的试剂盒，其以口服剂型形式包装，其使用说明书。

公开(公告)号：WO2019161211A3

公开(公告)日：2019-08-22

申请号：PCT/US2019/018230

申请日：2019-02-15

Applicant: NUSIRT SCIENCES, INC.

Inventor： ZEMEL, Michael ,  BRUCKBAUER, Antje ,  BANERJEE, Jheelam

IPC: A61K31/13 ,  A61K47/06 ,  A61K47/28 ,  C07J5/00 ,  C07J9/00 ,  C07J51/00

Abstract: Methods useful for reducing or preventing hepatic steatosis and NASH are provided herein. Such methods may comprise administering to a subject in need thereof an FXR agonist in combination with an amount of a branched amino acid in free amino acid form, such as leucine, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.